Table 2: Univariable analysis of cancer-specific and recurrence-free survivals (at 3-years of follow-up).

Factor DeadCancer-specific survival value RecurrenceRecurrence-free survival value

Gender
 Female191052.10.265151133.30.013
 Male552357.8472050.7
Age
 <62 yrs371946.40.324291637.70.546
 ≥62 yrs371465.2331554.1
Location
 Lip7183.30.4917183.30.383
 Tongue1057010820
 Floor of the mouth241061.320863.3
 Gingiva52604250
 Retromolar trigone11630.78437.5
 Hard palate9453.37442.9
 Buccal mucosa8537.56433.3
Tumor size
 T113188.9<0.00113483.30.009
 T229970.4281253.4
 T39530.58530
 T4231816.9131023.1
N status
 0411176.90.003371363.50.006
 112717.810718
 2171324.2131015.4
 342502150
Stage
 I12188.9<0.00112471.60.009
 II23677.422860
 III10533.39534.6
 IV292126.9191423.7
Tumor grade
 G1421367.80.037361555.70.195
 G2/G3322042.1261635.3
Treatment modality
 SG282876.20.050261055.20.134
 SG + RT232347.7211332.8
 CT + SG or RCT23 2337.815850
Margin status*
 Free of tumor33979.70.15731968.40.003
 With tumor241150.1231626.1
Perineural permeation
 Absent 662858.20.243542549.80.041
 Present8537.58625
Lymphatic invasion
 Absent 582755.10.849472446.50.824
 Present16661.115753.3
EMMPRIN expression
 0, 1+, 2+18388.50.01117858.80.882
 3+ (overexpression)583045.7452343.3
EMMPRIN distribution
 Homogeneous451859.20.503371850.50.898
 Heterogeneous (periphery)291550.7251339.6
EMMPRIN fibroblasts
 Absent 9620.80.0928618.80.088
 Present652760.1542550.6
Ki-67
 <50% (low expression)361269.40.111321456.20.560
 ≥50% (high expression)381145301739.7

SG: surgery; RT: radiotherapy; CT: chemotherapy; RCT: radiochemotherapy.
Not determined in the 17 cases.